Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cunermuspir in neuromuscular pain
NCT04737278Phase 2Completed
- Sponsor
- MitoSynergy
- Start
- Jan 2014
- Primary completion
- May 2014
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial (2 arms), sponsored by MitoSynergy. Primary endpoints: Neuromuscular Symptoms at 28 days and Platelet ATP at 28 days. Started Jan 2014; status: completed.
Beyond the preview
Go deeper on NCT04737278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04737278.